Dosing & Timing

Human dose ranges, practical timing notes, and current dosing limits for Urolithin A in oncology discussions

What human studies have used

Published human studies most often use:

250 mg/day
500 mg/day
1000 mg/day

These doses have mainly been studied in healthy or non-oncology populations, with some early oncology-specific interest now emerging.

Why 1000 mg/day comes up most often

The highest commonly cited human dose in the current literature is 1000 mg/day.

That is also the dose range showing up in some oncology-relevant clinical-trial settings.

That does not make it an established cancer dose.

It simply reflects where the research is now concentrating.

Timing considerations

No oncology-specific timing protocol has been established.

The practical points currently seem to be:

daily consistency likely matters more than exact clock timing
food timing appears flexible in the human data so far
active-treatment timing still needs clinician review

Why diet is not enough for dosing logic

Dietary intake of ellagitannin-rich foods is not a reliable way to produce predictable Urolithin A exposure.

That is because microbiome conversion varies so much between individuals.

If the goal is consistent exposure, direct supplementation makes more sense than relying on pomegranate or other precursor foods alone.

What is still not known

Several dosing questions remain open:

effective oncology-specific dose ranges
best dosing alongside chemotherapy, endocrine therapy, targeted therapy, or immunotherapy
whether higher oral dosing produces meaningfully better tumour-site effects
whether different cancer settings need different dosing logic

Bottom line

Urolithin A has a usable human dosing range in the literature.

It does not yet have a settled oncology dosing protocol.

That is why it should still be treated as investigational in cancer care.

Key References

Human safety, absorption, and plasma exposure of oral Urolithin A
https://pmc.ncbi.nlm.nih.gov/articles/PMC10460156/

Direct supplementation compared with dietary precursor exposure
https://www.nature.com/articles/s41430-021-00950-1

Urolithin A prostate-trial listing
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-03835

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.